MONTREAL, QUEBEC--(Marketwire - January 04, 2008) - MethylGene Inc. (TSX: MYG) announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for MGCD265, its multi-targeted (c-MET) kinase inhibitor. MGCD265 targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases, which appear to play key roles in tumor development and survival, blood vessel formation (angiogenesis) and cancer cell metastasis.
